{
  "source": "PA-Med-Nec-Omvoh.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2320-3\nProgram Prior Authorization/Medical Necessity\nMedication * Omvoh™ (mirikizumab-mrkz)\n*This program applies to the subcutaneous formulation of Omvoh.\nP&T Approval Date 1/2024, 1/2025, 3/2025\nEffective Date 5/1/2025\n1. Background:\nOmvoh (mirikizumab-mrkz) is an interleukin-23 antagonist indicated for the treatment of\nmoderately to severely active ulcerative colitis in adults and moderately to severely active Crohn's\ndisease in adults.\n2. Coverage Criteriaa:\nA. Ulcerative Colitis (UC)\n1. Initial Authorization for Maintenance Dosing\na. Omvoh will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active ulcerative colitis\n-AND-\n(2) One of the following:\n(a) Patient has been established on therapy with Omvoh under an active\nUnitedHealthcare medical benefit prior authorization for moderately to severely\nactive ulcerative colitis\n-OR-\n(b) Both of the following:\ni. Patient is currently on Omvoh therapy for moderately to severely active\nulcerative colitis as documented by claims history or submission of medical\nrecords (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from an Eli Lilly sponsored\nprogram (e.g., sample card which can be redeemed at a pharmacy for a free\nsupply of medication) as a means to establish as a current user of Omvoh*\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\n(3) Patient is not receiving Omvoh in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Entyvio (vedolizumab), Olumiant (baricitinib), Orencia (abatacept),\nRinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab),\nustekinumab, Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Zeposia\n(ozanimod)]\n-AND-\n(4) Prescribed by or in consultation with a gastroenterologist\n* Patients ",
    "umab), Skyrizi (risankizumab),\nustekinumab, Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Zeposia\n(ozanimod)]\n-AND-\n(4) Prescribed by or in consultation with a gastroenterologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from\nan Eli Lilly sponsored program shall be required to meet initial authorization criteria as if\npatient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Omvoh will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Omvoh therapy\n-AND-\n(2) Patient is not receiving Omvoh in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Entyvio (vedolizumab), Olumiant (baricitinib), Orencia (abatacept),\nRinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab),\nustekinumab, Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Zeposia\n(ozanimod)]\nAuthorization will be issued for 12 months.\nB. Crohn’s Disease (CD)\n1. Initial Authorization for Maintenance Dosing\na. Omvoh will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active Crohn’s disease\n-AND-\n(2) One of the following:\n© 2025 UnitedHealthcare Services, Inc.\n2\n(a) Patient has been established on therapy with Omvoh under an active\nUnitedHealthcare medical benefit prior authorization for moderately to severely\nactive Crohn’s disease\n-OR-\n(b) Both of the following:\ni. Patient is currently on Omvoh therapy for moderately to severely active\nCrohn’s disease as documented by claims history or submission of medical\nrecords (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from an Eli Lilly sponsored\nprogram (e.g., sample card which can",
    "py):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from an Eli Lilly sponsored\nprogram (e.g., sample card which can be redeemed at a pharmacy for a free\nsupply of medication) as a means to establish as a current user of Omvoh*\n-AND-\n(3) Patient is not receiving Omvoh in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib),\nSimponi (golimumab), Skyrizi (risankizumab-rzaa), ustekinumab, Xeljanz\n(tofacitinib)]\n-AND-\n(4) Prescribed by or in consultation with a gastroenterologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Omvoh will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Omvoh therapy\n-AND-\n(2) Patient is not receiving Omvoh in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib),\nSimponi (golimumab), Skyrizi (risankizumab-rzaa), ustekinumab, Xeljanz\n(tofacitinib)]\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n3\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n• The intravenous infusion of is typically covered under the medical benefit. Please refer to the\nUnitedHealthcare Drug Policy for Omvoh.\n4. Reference:\n1. Omvoh",
    "class.\n• Supply limits may be in place.\n• The intravenous infusion of is typically covered under the medical benefit. Please refer to the\nUnitedHealthcare Drug Policy for Omvoh.\n4. Reference:\n1. Omvoh [package insert]. Indianapolis, IN: Eli Lilly and Company; January 2025.\nProgram Prior Authorization/Medical Necessity - Omvoh (mirikizumab-mrkz)\nChange Control\n1/2024 New program\n1/2025 Annual review. Reworded criteria for established therapy through a\nmedical prior authorization for clarity and not to change clinical intent.\nUpdated examples with no change to clinical intent. Updated reference.\n3/2025 Added coverage criteria for Crohn’s disease. Updated background and\nreferences.\n© 2025 UnitedHealthcare Services, Inc.\n4"
  ]
}